Advertisement

Thrombophilia: Hereditary and Acquired

  • Seema Tyagi
  • Debdas Bose
  • Prasad Dange
Chapter

Abstract

The term thrombophilia (or hypercoagulability) denotes the presence of risk factors for the development of venous or/and arterial thrombosis. It could be inherited or acquired defect of haemostatic system [1].

Keywords

Thrombophilia Thrombosis Anticoagulation Lupus Factor V Leiden Protein C Protein S Antithrombin Homocysteine 

References

  1. 1.
    Pendleton RC, Rodgers GM. Chapter 55: Thrombosis and anti-thrombotic therapy. In: Wintrobe’s clinical hematology. 13th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins Health; 2014. p. 1218–1257.Google Scholar
  2. 2.
    Lee AD, Stephen E, Agarwal S, Premkumar P. Venous thrombo-embolism in India. Eur J Vasc Endovasc Surg. 2009;37:482–5.CrossRefGoogle Scholar
  3. 3.
    Agarwal S, Lee AD, Raju RS, Stephen E. Venous thrombo-embolism: a problem in Indian/Asian polulation? Indian J Urol. 2009;25(1):11–6.CrossRefGoogle Scholar
  4. 4.
    Moll S. Thrombophilia: clinical–practical aspects. J Thromb Thrombolysis. 2015;39:367–78.CrossRefGoogle Scholar
  5. 5.
    Middeldorp S. Inherited thrombophilia: a double edged sword. Hematology Am Soc Hematol Educ Program. 2016;(1):1–9.CrossRefGoogle Scholar
  6. 6.
    American College of Obstetricians and Gynecologists Women’s Health Care Physicians. ACOG practice bulletin no.138: inherited thrombophilia in pregnancy. Obstet Gynecol. 2013;122(3):706–17.CrossRefGoogle Scholar
  7. 7.
    Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177–87.CrossRefGoogle Scholar
  8. 8.
    APLA Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737.CrossRefGoogle Scholar
  9. 9.
    Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010–21.CrossRefGoogle Scholar
  10. 10.
    Harris EN, Pierangeli SS. Primary, secondary, and catastrophic antiphospholipid syndrome: what’s in a name? Semin Thromb Hemost. 2008;34(3):219–26.CrossRefGoogle Scholar
  11. 11.
    Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012;71(2):242–4.CrossRefGoogle Scholar
  12. 12.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295.CrossRefGoogle Scholar
  13. 13.
    Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498.CrossRefGoogle Scholar
  14. 14.
    CLSI. Laboratory testing for the lupus anticoagulant; approved guideline. CLSI document H60-A. Wayne: Clinical and Laboratory Standards Institute; 2014.Google Scholar
  15. 15.
    Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014;40(2):163–71.CrossRefGoogle Scholar
  16. 16.
    Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004;103:4173.CrossRefGoogle Scholar
  17. 17.
    Guasch JF, Lensen RP, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance. Thromb Haemost. 1997;77:252.CrossRefGoogle Scholar
  18. 18.
    Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81:193.CrossRefGoogle Scholar
  19. 19.
    Trossaërt M, Conard J, Horellou MH, et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost. 1996;75:521.PubMedGoogle Scholar
  20. 20.
    Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64.CrossRefGoogle Scholar
  21. 21.
    AT Kumar R, Chan AK, Dawson JE, et al. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol. 2014;166:130.CrossRefGoogle Scholar
  22. 22.
  23. 23.
    Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost. 1998;24:19.CrossRefGoogle Scholar
  24. 24.
    Gaustadnes M, Rüdiger N, Rasmussen K, Ingerslev J. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost. 2000;83(4):554–8.CrossRefGoogle Scholar
  25. 25.
    D’Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolatereductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost. 2000;83:563.CrossRefGoogle Scholar
  26. 26.
    Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023.CrossRefGoogle Scholar
  27. 27.
    Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA Study. Stroke. 2003;34:1130.CrossRefGoogle Scholar
  28. 28.
    Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA. 1999;281:2113.CrossRefGoogle Scholar
  29. 29.
    Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279.CrossRefGoogle Scholar
  30. 30.
    Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 1996;94:2154.CrossRefGoogle Scholar
  31. 31.
    Reitsma PH. Protein C deficiency: from gene defects to disease. Thromb Haemost. 1997;78:344.CrossRefGoogle Scholar
  32. 32.
    Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism—results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444.CrossRefGoogle Scholar
  33. 33.
    Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis. 1998;28:25.PubMedGoogle Scholar
  34. 34.
    Koenen RR, Tans G, van Oerle R, et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood. 2003;102:1686.CrossRefGoogle Scholar
  35. 35.
    Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol. 2008;143:409.CrossRefGoogle Scholar
  36. 36.
    Dahlbäck B. C4b-binding protein: a forgotten factor in thrombosis and hemostasis. Semin Thromb Hemost. 2011;37:355.CrossRefGoogle Scholar
  37. 37.
    Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of mutations—summary of the first update. Thromb Haemost. 2000;84:918.CrossRefGoogle Scholar
  38. 38.
    Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood. 1986;67:504.PubMedGoogle Scholar
  39. 39.
    Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706.CrossRefGoogle Scholar
  40. 40.
    Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114:885–9.CrossRefGoogle Scholar
  41. 41.
    Cooper PC, Rezende SM. An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. Int J Lab Hematol. 2007;29:153.CrossRefGoogle Scholar
  42. 42.
    Gomez E, van der Poel SC, Jansen JH, et al. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood. 1998;91:2208.PubMedGoogle Scholar
  43. 43.
    Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I22–30.PubMedGoogle Scholar
  44. 44.
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S.CrossRefGoogle Scholar
  45. 45.
    Kitchens CS. How I treat superficial venous thrombosis. Blood. 2011;117(1):39–44.CrossRefGoogle Scholar
  46. 46.
    Leon L, Giannoukas AD, Dodd D, Chan P, Labropoulos N. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg. 2005;29(1):10–7.CrossRefGoogle Scholar
  47. 47.
    Baglin T, Keeling D. Chapter 47, Management of venous thromboembolism. In: Postgraduate haematology. 7th ed. West Sussex: Wiley Blackwell; 2016. p. 830–7.Google Scholar
  48. 48.
    Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41:32–67.CrossRefGoogle Scholar
  49. 49.
    Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolismprovoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710–6.CrossRefGoogle Scholar
  50. 50.
    Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;343:d3036.CrossRefGoogle Scholar
  51. 51.
    Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–25.CrossRefGoogle Scholar
  52. 52.
    Eichenger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosisor pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–6.CrossRefGoogle Scholar
  53. 53.
    Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123(12):1794–801.CrossRefGoogle Scholar
  54. 54.
    Milling TJ Jr, Frontera J. Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding. Am J Manag Care. 2017;23(4 Suppl):S67–80.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, et al. The ASH Choosing Wisely campaign: five hematologic tests and treatments to question. Blood. 2013;122:3879–83.CrossRefGoogle Scholar
  56. 56.
    National Clinical Guideline centre (UK). Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing [Internet]. London: Royal College of Physicians (UK); 2012.Google Scholar
  57. 57.
    Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Seema Tyagi
    • 1
  • Debdas Bose
    • 1
  • Prasad Dange
    • 1
  1. 1.Department of HematologyAIIMSNew DelhiIndia

Personalised recommendations